Relias Media - Continuing Medical Education Publishing

The trusted source for

healthcare information and

CONTINUING EDUCATION.

  • Sign In
  • Sign Out
  • MyAHC
    • Home
      • Home
      • Newsletters
      • Blogs
      • Archives
      • CME/CE Map
      • Shop
    • Emergency
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • Hospital
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • Clinical
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • All Access
      • My Subscription
      • Subscribe Now
    • My Account
      • My Subscriptions
      • My Content
      • My Orders
      • My CME/CE
      • My Transcript
    Home » Neurologic Complications of Checkpoint Inhibitors
    ABSTRACT & COMMENTARY

    Neurologic Complications of Checkpoint Inhibitors

    December 1, 2017
    No Comments
    Reprints
    Facebook Twitter Linkedin Share Share

    Related Articles

    Polyradiculoneuropathy from Immune Checkpoint Inhibitors

    Checkpoint Inhibitors: The First Effective Therapy for Progressive Multifocal Leukoencephalopathy?

    Neurologic Complications of Bladder Cancer

    Related Products

    Neonatal Neurologic Emergencies

    Neurologic Disease and Criminal Behavior – A Medicolegal Conundrum

    Keywords

    Immunotherapy

    By Michael Rubin, MD

    Professor of Clinical Neurology, Weill Cornell Medical College

    Dr. Rubin reports no financial relationships relevant to this field of study.

    SYNOPSIS: Anti-programmed death 1 antibodies (checkpoint inhibitors) have become a mainstay in the treatment of many types of cancers, and now are known to cause frequent neuromuscular adverse effects that can cause severe disability or death if not recognized or treated promptly.

    SOURCE: Kao JC, Liao B, Markovic SN, et al. Neurological complications associated with anti-programmed death 1 (PD-1) antibodies. JAMA Neurol 2017;74:1216-1222.

    Anti-programmed death 1 (PD-1) antibodies, originally approved in the United States for the treatment of melanoma in 2014 and for non-small cell lung cancer in 2015, are used for the treatment of solid-organ tumors, including renal cell cancer, head and neck cancer, urothelial cancer, and Hodgkin’s lymphoma. Phase III trials are underway for other tumors, including bladder, ovarian, and brain. Adverse events, as initially reported, were thought to be rare, occurring in < 1% of patients, and included thyroid dysfunction, pneumonitis, colitis, hepatitis, nephritis, hypophysitis, uveitis, type 1 diabetes, and myositis. However, reports of neurological complications associated with anti-PD-1 therapy are increasing, and most often are neuromuscular in nature, including myasthenia gravis, necrotizing myopathy, vasculitic neuropathy, and polyradiculoneuropathy, as well as focal seizures associated with inflammatory cerebral lesions on magnetic resonance imaging, limbic encephalitis, and retinopathy. What are the frequency, phenotype, and severity of neurological complications from PD-1 antibody use?

    In a single-center, retrospective, cohort study, undertaken by the departments of Neurology, Oncology, and Pharmacy Services at the Mayo Clinic from September 2014 to May 2016, using the Mayo Cancer Pharmacy Database, patients who received anti-PD-1 monoclonal antibodies (pembrolizumab or nivolumab) for the treatment of malignant melanoma or other solid organ tumor and developed neurologic disorders within 12 months of anti-PD-1 antibody use were identified. Neurologic symptoms attributable to metastatic disease or other cancer treatment were excluded. Severity was measured using the modified Rankin Scale.

    Among 347 patients who received anti-PD-1 antibody, 204 received pembrolizumab, 142 received nivolumab, and one received both. Neurologic complications occurred in 10 patients (2.9%), eight men and two women, after a median of 5.5 cycles of anti-PD-1 therapy, seven during pembrolizumab and three during nivolumab treatment. Myopathy (n = 2), one mild and one severe necrotizing, and neuropathy (n = 4), axonal, demyelinating, or mixed, were the most common adverse events, with individual cases of cerebellar ataxia, autoimmune retinopathy, bilateral internuclear ophthalmoplegia, and headache. Time to maximum symptom severity varied from one to 90+ days. One patient died, and nine improved, one spontaneously and eight with immunotherapy, including intravenous immunoglobulin, corticosteroid, and plasma exchange. Non-neurologic, immune-mediated, adverse events occurred in five of these patients as well, including hypothyroidism (n = 3), colitis (n = 2), and hepatitis (n = 1). Anti-PD-1 neurologic adverse events may be rapid and life threatening, necessitating prompt recognition and withdrawal of the inciting agent.

    COMMENTARY

    Cancer immunotherapy, initiated in 1891 when New York surgeon William Coley injected bacterial products into a sarcoma and watched it shrink, has today joined surgery, radiation, and chemotherapy as a pillar of cancer treatment. Initially focused on accelerating T cell activity, today immunotherapy involves immune-checkpoint inhibitors, such as PD-1 monoclonal antibodies, which “release the immune system’s brakes to unleash anti-tumor immune responses.” Discovered in 1992, PD-1 is expressed on B cells and peripheral-activated CD4+ and CD8+ T cells, and suppresses T-cell activation, proliferation, and effector function. Thus, PD-1 blockade activates an antitumor immune system, preferentially recognizing tumor-derived antigens, rather than self-antigens. Immune-related adverse events may occur at any time but most occur during the first four months, with skin, gastrointestinal, and hepatic complications occurring early, within the first two months, and pulmonary, endocrine, and renal adverse events occurring beyond two months. Patients who fail to respond to immunotherapy may lack preexisting antitumor T-cell responses, and combination immune-checkpoint inhibitor therapy trials are underway to address this issue.1

    REFERENCE

    1. Iwai Y, Hamanishi J, Chamoto K, Honio T. Cancer immunotherapies targeting the PD-1 signaling pathway. J Biomed Sci 2017;24:26. doi: 10.1186/s12929-017-0329-9.

    Post a comment to this article

    Report Abusive Comment

    www.reliasmedia.com

    Neurology Alert

    View PDF
    Neurology Alert (Vol. 37, No. 4) - December 2017
    December 1, 2017

    Table Of Contents

    Treatment for Spinal Muscular Atrophy

    Neurologic Consequences of Zika Virus Infection

    MRI-guided FUS Thalamotomy for Medically Refractory Parkinson’s Tremor

    Optimizing Brain Oxygen in Severe Traumatic Brain Injury

    Systemic Immune Activation and the Course of Amyotrophic Lateral Sclerosis

    Neurologic Complications of Checkpoint Inhibitors

    Begin Test

    Buy this Issue/Course

    Clinical Briefs in Primary Care

    Pharmacology Watch

    Financial Disclosure: Neurology Alert’s editor in chief, Matthew Fink, MD, reports he is a consultant for Procter & Gamble. Peer reviewer M. Flint Beal, MD; executive editor Leslie Coplin; editor Jonathan Springston; and editorial group manager Terrey L. Hatcher report no financial relationships relevant to this field of study.

    Shop Now: Search Products

    • Subscription Publications
    • Books & Study Guides
    • Webinars
    • Group & Site
      Licenses
    • State CME/CE
      Requirements

    Webinars And Events

    View All Events
    • Home
      • Home
      • Newsletters
      • Blogs
      • Archives
      • CME/CE Map
      • Shop
    • Emergency
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • Hospital
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • Clinical
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • All Access
      • My Subscription
      • Subscribe Now
    • My Account
      • My Subscriptions
      • My Content
      • My Orders
      • My CME/CE
      • My Transcript
    • Help
    • Search
    • About Us
    • Sign In
    • Register
    Relias Media - Continuing Medical Education Publishing

    The trusted source for

    healthcare information and

    CONTINUING EDUCATION.

    Customer Service

    customerservice@reliasmedia.com

    U.S. and Canada: 1-800-688-2421 x 2

    International +1-404-262-5476 x 2

    Accounts Receivable

    1-800-688-2421 x 3
    ReliasMedia_AR@reliasmedia.com

    Sales

    1-800-688-2421 x 1

    Mailing Address

    • 1010 Sync St., Suite 100
      Morrisville, NC 27560-5468
      USA

    © 2022 Relias. All rights reserved.

    Do Not Sell My Personal Information  Privacy Policy  Terms of Use  Contact Us  Reprints  Group Sales

    For DSR inquiries or complaints, please reach out to Wes Vaux, Data Privacy Officer, DPO@relias.com

    Design, CMS, Hosting & Web Development :: ePublishing